{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T01:17:16Z","timestamp":1771982236084,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,1]]},"DOI":"10.7759\/cureus.21812","type":"journal-article","created":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T20:00:50Z","timestamp":1643745650000},"source":"Crossref","is-referenced-by-count":3,"title":["Pneumocystis jirovecii Pneumonia in Three Patients With Breast Cancer Receiving Neoadjuvant Dose-Dense Chemotherapy"],"prefix":"10.7759","author":[{"given":"Ritsuya","family":"Shiiba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Himeji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoichi","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gen-ichi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Otomo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Pneumocystis carinii pneumonia in patients with solid tumors and lymphomas: predisposing factors and outcome","volume":"25","author":"Barbounis V","year":"2005","unstructured":"Barbounis V, Aperis G, Gambletsas E, Koumakis G, Demiris M, Vassilomanolakis M, Efremidis A. Pneumocystis carinii pneumonia in patients with solid tumors and lymphomas: predisposing factors and outcome. Anticancer Res. 2005, 25:651-55.","journal-title":"Anticancer Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-014-2597-1","article-title":"Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel\/cyclophosphamide chemotherapy","volume":"23","author":"Kosaka Y","year":"2015","unstructured":"Kosaka Y, Rai Y, Masuda N, et al.. Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel\/cyclophosphamide chemotherapy. Support Care Cancer. 2015, 23:1137-43. 10.1007\/s00520-014-2597-1","journal-title":"Support Care Cancer"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62048-1","article-title":"Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 \u00d7 2 factorial, randomised phase 3 trial","volume":"385","author":"Del Mastro L","year":"2015","unstructured":"Del Mastro L, De Placido S, Bruzzi P, et al.. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 \u00d7 2 factorial, randomised phase 3 trial. Lancet. 2015, 385:1863-72. 10.1016\/S0140-6736(14)62048-1","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-015-3573-2","article-title":"Pneumocystis jiroveci pneumonia (PCP) in patients receiving neoadjuvant and adjuvant anthracycline-based chemotherapy for breast cancer: incidence and risk factors","volume":"154","author":"Waks AG","year":"2015","unstructured":"Waks AG, Tolaney SM, Galar A, et al.. Pneumocystis jiroveci pneumonia (PCP) in patients receiving neoadjuvant and adjuvant anthracycline-based chemotherapy for breast cancer: incidence and risk factors. Breast Cancer Res Treat. 2015, 154:359-67. 10.1007\/s10549-015-3573-2","journal-title":"Breast Cancer Res Treat"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.09.081","article-title":"Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741\/Cancer and Leukemia Group B Trial 9741","volume":"21","author":"Citron ML","year":"2003","unstructured":"Citron ML, Berry DA, Cirrincione C, et al.. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741\/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003, 21:1431-9. 10.1200\/JCO.2003.09.081","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.3907-19","article-title":"Pneumocystis jirovecii pneumonia in a patient with breast cancer receiving neoadjuvant dose-dense chemotherapy","volume":"59","author":"Watanabe H","year":"2020","unstructured":"Watanabe H, Kitahara Y, Murakami Y, et al.. Pneumocystis jirovecii pneumonia in a patient with breast cancer receiving neoadjuvant dose-dense chemotherapy. Intern Med. 2020, 59:987-90. 10.2169\/internalmedicine.3907-19","journal-title":"Intern Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/rcr2.459","article-title":"Pneumocystis jirovecii in a patient on dose-dense chemotherapy for early breast cancer","volume":"7","author":"Khoo C","year":"2019","unstructured":"Khoo C, Gilchrist J, Williamson JP, Paul M, Kefford R. Pneumocystis jirovecii in a patient on dose-dense chemotherapy for early breast cancer. Respirol Case Rep. 2019, 7:e00459. 10.1002\/rcr2.459","journal-title":"Respirol Case Rep"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1159\/000487713","article-title":"Clinical, diagnostic, and treatment disparities between HIV-infected and non-HIV-infected immunocompromised patients with Pneumocystis jirovecii pneumonia","volume":"96","author":"Salzer HJ","year":"2018","unstructured":"Salzer HJ, Sch\u00e4fer G, Hoenigl M, et al.. Clinical, diagnostic, and treatment disparities between HIV-infected and non-HIV-infected immunocompromised patients with Pneumocystis jirovecii pneumonia. Respiration. 2018, 96:52-65. 10.1159\/000487713","journal-title":"Respiration"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-021-02289-0","article-title":"Interstitial lung disease associated with adjuvant and neoadjuvant chemotherapy in early breast cancer","volume":"19","author":"Tezuka K","year":"2021","unstructured":"Tezuka K, Miura K, Nakano Y, et al.. Interstitial lung disease associated with adjuvant and neoadjuvant chemotherapy in early breast cancer. World J Surg Oncol. 2021, 19:169. 10.1186\/s12957-021-02289-0","journal-title":"World J Surg Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.9.1483","article-title":"Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15","volume":"8","author":"Fisher B","year":"1990","unstructured":"Fisher B, Brown AM, Dimitrov NV, et al.. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol. 1990, 8:1483-96. 10.1200\/JCO.1990.8.9.1483","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0707056","article-title":"Weekly paclitaxel in the adjuvant treatment of breast cancer","volume":"358","author":"Sparano JA","year":"2008","unstructured":"Sparano JA, Wang M, Martino S, et al.. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008, 358:1663-71. 10.1056\/NEJMoa0707056","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.4.931","article-title":"Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23","volume":"19","author":"Fisher B","year":"2001","unstructured":"Fisher B, Anderson S, Tan-Chiu E, et al.. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol. 2001, 19:931-42. 10.1200\/JCO.2001.19.4.931","journal-title":"J Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.7485-21","article-title":"Pneumocystis pneumonia in a patient with ovarian cancer receiving olaparib therapy: a case report","volume":"61","author":"Himeji D","year":"2022","unstructured":"Himeji D, Tanaka GI, Shiiba R, et al..  Pneumocystis pneumonia in a patient with ovarian cancer receiving olaparib therapy: a case report. Intern Med. 2022, 61:217-21. 10.2169\/internalmedicine.7485-21","journal-title":"Intern Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.4046\/trd.2020.0015","article-title":"Recent advances in the diagnosis and management of Pneumocystis pneumonia","volume":"83","author":"Tasaka S","year":"2020","unstructured":"Tasaka S. Recent advances in the diagnosis and management of Pneumocystis pneumonia. Tuberc Respir Dis (Seoul). 2020, 83:132-40. 10.4046\/trd.2020.0015","journal-title":"Tuberc Respir Dis (Seoul)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2014.07.001","article-title":"Serum (1 \u2192 3) \u03b2-D-glucan assay for discrimination between Pneumocystis jirovecii pneumonia and colonization","volume":"20","author":"Tasaka S","year":"2014","unstructured":"Tasaka S, Kobayashi S, Yagi K, et al.. Serum (1 \u2192 3) \u03b2-D-glucan assay for discrimination between Pneumocystis jirovecii pneumonia and colonization. J Infect Chemother. 2014, 20:678-81. 10.1016\/j.jiac.2014.07.001","journal-title":"J Infect Chemother"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2072-1439.2015.12.27","article-title":"Diagnosis of pneumocystis pneumonia using serum (1-3)-\u03b2-D-Glucan: a bivariate meta-analysis and systematic review","volume":"7","author":"Li WJ","year":"2015","unstructured":"Li WJ, Guo YL, Liu TJ, Wang K, Kong JL. Diagnosis of pneumocystis pneumonia using serum (1-3)-\u03b2-D-Glucan: a bivariate meta-analysis and systematic review. J Thorac Dis. 2015, 7:2214-25. 10.3978\/j.issn.2072-1439.2015.12.27","journal-title":"J Thorac Dis"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00013-12","article-title":"Colonization by Pneumocystis jirovecii and its role in disease","volume":"25","author":"Morris A","year":"2012","unstructured":"Morris A, Norris KA. Colonization by Pneumocystis jirovecii and its role in disease. Clin Microbiol Rev. 2012, 25:297-317. 10.1128\/CMR.00013-12","journal-title":"Clin Microbiol Rev"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.2008-740ST","article-title":"An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients","volume":"183","author":"Limper AH","year":"2011","unstructured":"Limper AH, Knox KS, Sarosi GA, et al.. An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med. 2011, 183:96-128. 10.1164\/rccm.2008-740ST","journal-title":"Am J Respir Crit Care Med"},{"key":"ref19","article-title":"Risk factors for Pneumocystis carinii pneumonia in patients with polymyositis\/dermatomyositis or systemic lupus erythematosus","volume":"23","author":"Kadoya A","year":"1996","unstructured":"Kadoya A, Okada J, Iikuni Y, et al.. Risk factors for Pneumocystis carinii pneumonia in patients with polymyositis\/dermatomyositis or systemic lupus erythematosus. J Rheumatol. 1996, 23:1186-8.","journal-title":"J Rheumatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.4065\/82.9.1052","article-title":"Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials","volume":"82","author":"Green H","year":"2007","unstructured":"Green H, Paul M, Vidal L, Leibovici L. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc. 2007, 82:1052-9. 10.4065\/82.9.1052","journal-title":"Mayo Clin Proc"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/83015-pneumocystis-jirovecii-pneumonia-in-three-patients-with-breast-cancer-receiving-neoadjuvant-dose-dense-chemotherapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:36:19Z","timestamp":1707507379000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/83015-pneumocystis-jirovecii-pneumonia-in-three-patients-with-breast-cancer-receiving-neoadjuvant-dose-dense-chemotherapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,1]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.21812","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2,1]]}}}